Twist Bioscience (NASDAQ:TWST) Stock Price Up 5.4%

Twist Bioscience Co. (NASDAQ:TWST) traded up 5.4% during trading on Tuesday . The stock traded as high as $39.28 and last traded at $39.28. 407,370 shares were traded during trading, a decline of 60% from the average session volume of 1,010,725 shares. The stock had previously closed at $37.26.

Analyst Ratings Changes

TWST has been the topic of a number of analyst reports. Guggenheim assumed coverage on Twist Bioscience in a research note on Tuesday, June 4th. They set a “buy” rating and a $53.00 target price on the stock. TD Cowen raised their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. The Goldman Sachs Group increased their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, July 9th. Robert W. Baird increased their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Finally, JPMorgan Chase & Co. boosted their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.22.

Twist Bioscience Stock Up 0.5 %

The firm’s fifty day moving average is $47.71 and its 200-day moving average is $42.70. The stock has a market capitalization of $2.61 billion, a PE ratio of -13.26 and a beta of 1.76.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. During the same quarter in the prior year, the firm earned ($1.01) earnings per share. Twist Bioscience’s quarterly revenue was up 27.7% on a year-over-year basis. On average, analysts expect that Twist Bioscience Co. will post -3.13 EPS for the current year.

Insider Buying and Selling

In related news, CEO Emily M. Leproust sold 1,732 shares of the stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $49.41, for a total value of $85,578.12. Following the transaction, the chief executive officer now directly owns 505,846 shares of the company’s stock, valued at approximately $24,993,850.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Emily M. Leproust sold 1,732 shares of Twist Bioscience stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $49.41, for a total transaction of $85,578.12. Following the sale, the chief executive officer now owns 505,846 shares in the company, valued at $24,993,850.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dennis Cho sold 709 shares of the firm’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $28,310.37. Following the sale, the insider now directly owns 78,996 shares of the company’s stock, valued at $3,154,310.28. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,483 shares of company stock worth $781,448. 3.92% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TWST. Victory Capital Management Inc. bought a new stake in Twist Bioscience in the 4th quarter valued at about $274,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Twist Bioscience by 1.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 448,232 shares of the company’s stock worth $16,522,000 after acquiring an additional 5,728 shares during the last quarter. QRG Capital Management Inc. boosted its position in shares of Twist Bioscience by 9.3% in the 4th quarter. QRG Capital Management Inc. now owns 60,580 shares of the company’s stock valued at $2,233,000 after purchasing an additional 5,142 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Twist Bioscience by 29.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock valued at $46,732,000 after acquiring an additional 284,884 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. grew its holdings in shares of Twist Bioscience by 2.9% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock valued at $131,835,000 after buying an additional 99,511 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.